keyword
MENU ▼
Read by QxMD icon Read
search

CD30

keyword
https://www.readbyqxmd.com/read/29676455/ethnic-disparity-in-primary-cutaneous-cd30-t-cell-lymphoproliferative-disorders-an-analysis-of-1496-cases-from-the-us-national-cancer-database
#1
EDITORIAL
Andrew L Feldman, Christopher R Flowers
No abstract text is available yet for this article.
April 20, 2018: British Journal of Haematology
https://www.readbyqxmd.com/read/29676444/ethnic-disparity-in-primary-cutaneous-cd30-t-cell-lymphoproliferative-disorders-an-analysis-of-1496-cases-from-the-us-national-cancer-database
#2
Chang Su, Kevin A Nguyen, Harrison X Bai, Cheryl K Zogg, Ya Cao, Giorgos Karakousis, Paul J Zhang, Guiying Zhang, Rong Xiao
Primary cutaneous CD30+ T cell lymphoproliferative disorders (PCLPD), the second most common type of primary cutaneous T cell lymphomas, accounts for approximately 25-30% of cutaneous T-cell lymphoma cases. However, only small retrospective studies have been reported. We aimed to identify prognostic factors and evaluate the overall survival (OS) of patients with PCLPD stratified by ethnicity. We identified 1496 patients diagnosed with PCLPD between 2004 and 2014 in the US National Cancer Database. Chi-square test and anova were used to evaluate differences in demographic and disease characteristics, socioeconomic factors and treatments received...
April 20, 2018: British Journal of Haematology
https://www.readbyqxmd.com/read/29676371/methotrexate-associated-epstein-barr-virus-mucocutaneous-ulcer-a-case-report-and-review-of-literature
#3
Priyanka Yogendra Ravi, Elanthenral Sigamani, Yasir Jeelani, Marie Therese Manipadam
Epstein-Barr virus-positive mucocutaneous ulcer (EBVMCU) comprises part of the spectrum of B-cell lymphoproliferative disorders, reported in settings of immunosenescence and iatrogenic immunosuppression, affecting the oropharyngeal mucosa, skin, and gastrointestinal tract. We report a case of a 59-year-old female, known case of rheumatoid arthritis on methotrexate (MTX) for 15 years, who presented with an ulcer in the inner aspect of her cheek region for 2 years. Clinical examination revealed an infiltrative lesion involving the lower gingivobuccal sulcus of size 2 cm × 3 cm extending to the alveolus with level I lymph nodes, suspicious for carcinoma buccal mucosa...
April 2018: Indian Journal of Pathology & Microbiology
https://www.readbyqxmd.com/read/29673751/-primary-cutaneous-cd30-t-cell-lymphoproliferation-during-treatment-with-fingolimod-case-report-and-literature-review
#4
E Cesbron, J-B Monfort, C Giannesini, P Duriez, P Moguelet, P Senet, C Francès, A Barbaud, F Chasset
BACKGROUND: Fingolimod is an oral immunomodulator approved for relapsing-remitting multiple sclerosis. We report a case of a primary cutaneous CD30+ T-cell lymphoproliferation occurring 6 months after initiation of fingolimod. Based on a systematic literature review, the characteristics of these fingolimod-induced lymphoproliferative disorders are described. PATIENTS AND METHODS: A 56-year-old woman developed cutaneous indurated and ulcerated nodular lesions 6 months after starting fingolimod for active relapsing-remitting multiple sclerosis...
April 16, 2018: Annales de Dermatologie et de Vénéréologie
https://www.readbyqxmd.com/read/29669178/the-utility-of-multiparametric-flow-cytometry-in-the-detection-of-primary-effusion-lymphoma-pel
#5
Jacobo Galán, Isaac Martin, Itziar Carmona, José María Rodriguez-Barbero, Esperanza Cuadrado, Luis García-Alonso, José Antonio García-Vela
Primary effusion lymphoma (PEL) is a rare B cell lymphoproliferative disorder that arises predominantly in body cavities causing malignant effusions.The incidence of PEL is very low, accounting for approximately 4% of all HIV-associated non-Hodgkin lymphomas. PEL has also been described in elderly patients and after solid-organ transplantation. It is associated in all cases with human herpesvirus 8 (HHV8). We describe a case of PEL in a 88-year-old HIV-negative woman who presented with progressive dyspnea and moderate right-sided pleural effusion without significate lymphadenopathies or other effusions...
April 18, 2018: Cytometry. Part B, Clinical Cytometry
https://www.readbyqxmd.com/read/29666157/cd30-expression-and-its-correlation-with-myc-and-bcl2-in-de-novo-diffuse-large-b-cell-lymphoma
#6
Qi-Xing Gong, Zhen Wang, Chong Liu, Xiao Li, Ting-Xun Lu, Jin-Hua Liang, Wei Xu, Jian-Yong Li, Zhi-Hong Zhang
AIM: CD30+ diffuse large B-cell lymphoma (DLBCL) has emerged as a new immunophenotypic variant of de novo DLBCLs. However, the prevalence of CD30 positivity is variable according to different studies, and the prognostic significance of CD30 is also controversial. This study aimed to investigate the positive expression rate and prognostic impact of CD30 in de novo DLBCLs and try to find the correlated influences. METHODS: A total of 241 patients with de novo DLBCL in east China from 2008 to 2015 were included to investigate the prevalence, clinicopathological features and outcomes of CD30+ de novo DLBCLs...
April 17, 2018: Journal of Clinical Pathology
https://www.readbyqxmd.com/read/29662666/cd30-expression-and-survival-in-extranodal-nk-t-cell-lymphoma-a-systematic-review-and-meta-analysis
#7
Zihang Chen, Pujun Guan, Tong Shan, Yunxia Ye, Limin Gao, Zhi Wang, Sha Zhao, Wenyan Zhang, Li Zhang, Ling Pan, Weiping Liu
Background: The paradoxical reports about the prognostic value of the CD30 expression in extranodal NK/T-cell lymphoma (ENKTL) have restricted its further applications in clinical practice. To identify the common effects and the variation, we conducted this systematic review and meta-analysis. Methods: PubMed, MEDLINE, Embase, and Web of Science were searched between January 1975 and 31 January 2017. The pooled hazard ratio was used to estimate the effect of the CD30 expression on overall survival...
March 27, 2018: Oncotarget
https://www.readbyqxmd.com/read/29661425/soluble-cd30-acute-rejection-and-graft-survival-pre-and-6-month-post-transplant-determinations-when-is-the-best-time-to-measure
#8
M I de Holanda, T Matuck, D D B M de Carvalho, E M F L Domingues, R Curvo, D S Glasberg, A M G Santos, Á M Borela, L C Pôrto
BACKGROUND: Pretransplantation soluble CD30 (sCD30) has been shown to be a good predictor of acute rejection (AR) and graft loss. This study aimed to evaluate the effectiveness of sCD30 measured pretransplant and up to 6 months after transplantation as a predictor of AR, graft loss, and survival at 5 years post-transplantation. Subjects were patients receiving living donor renal transplants at Bonsucesso Federal Hospital (Rio de Janeiro) in 2006 and between August 2010 and May 2011. METHODS: sCD30 was analyzed in samples collected pretransplantation and 7, 14, and 21, 28 days and 3, 4, 5, and 6 months post-transplantation from 73 kidney recipients...
April 2018: Transplantation Proceedings
https://www.readbyqxmd.com/read/29660166/lymphomatoid-papulosis-with-folliculotropism-eccrinotropism-and-neurotropism
#9
Wei Ba, Yi Yang, Ziyan Zhang, Xuanjin Wei, Wenjuan Wang, Zigang Zhao, Liqiang Zheng, Chengxin Li
The histopathological characteristics of lymphomatoid papulosis (LyP) vary. Currently, six subtypes have been reported, including a new subtype with perifollicular infiltration and different degrees of folliculotropism of CD30+ atypical lymphocytes, known as follicular LyP. However, LyP pathologically manifesting with folliculotropism, eccrinotropism and neurotropism has been rarely reported. We present a case of LyP demonstrating CD30+ atypical lymphocytes around the hair follicle, eccrine gland and neurofiber, with varying degrees of infiltrates...
April 16, 2018: Journal of Cutaneous Pathology
https://www.readbyqxmd.com/read/29656112/influence-of-immunosuppressive-drugs-on-the-cd30-molecule-in-kidney-transplanted-patients
#10
Patricia Cristina Grenzi, Érika Fernandes Campos, Hélio Tedesco-Silva, Claudia Rosso Felipe, Maria Fernanda Soares, José Medina-Pestana, Hinrich Peter Hansen, Maria Gerbase-DeLima
BACKGROUND: Soluble CD30 (sCD30) is a suggested marker for kidney transplantation outcomes. We investigated whether sCD30 serum levels are influenced by immunosuppression and whether they correlate with findings in protocol biopsies and with CD30 gene expression in peripheral blood mononuclear cells (PBMC). METHODS: We studied 118 kidney transplant recipients that initially received tacrolimus (TAC) and, at month-3, were converted or not to sirolimus (SRL). RESULTS: sCD30 serum levels gradually declined after transplantation, being the decline more pronounced in the SRL group...
April 12, 2018: Human Immunology
https://www.readbyqxmd.com/read/29617304/the-pathological-spectrum-of-systemic-anaplastic-large-cell-lymphoma-alcl
#11
REVIEW
Ivonne A Montes-Mojarro, Julia Steinhilber, Irina Bonzheim, Leticia Quintanilla-Martinez, Falko Fend
Anaplastic large cell lymphoma (ALCL) represents a group of malignant T-cell lymphoproliferations that share morphological and immunophenotypical features, namely strong CD30 expression and variable loss of T-cell markers, but differ in clinical presentation and prognosis. The recognition of anaplastic lymphoma kinase (ALK) fusion proteins as a result of chromosomal translocations or inversions was the starting point for the distinction of different subgroups of ALCL. According to their distinct clinical settings and molecular findings, the 2016 revised World Health Organization (WHO) classification recognizes four different entities: systemic ALK-positive ALCL (ALK+ ALCL), systemic ALK-negative ALCL (ALK− ALCL), primary cutaneous ALCL (pC-ALCL), and breast implant-associated ALCL (BI-ALCL), the latter included as a provisional entity...
April 4, 2018: Cancers
https://www.readbyqxmd.com/read/29601554/treatment-options-for-paediatric-anaplastic-large-cell-lymphoma-alcl-current-standard-and-beyond
#12
REVIEW
Nina Prokoph, Hugo Larose, Megan S Lim, G A Amos Burke, Suzanne D Turner
Anaplastic Lymphoma Kinase (ALK)-positive Anaplastic Large Cell Lymphoma (ALCL), remains one of the most curable cancers in the paediatric setting; multi-agent chemotherapy cures approximately 65-90% of patients. Over the last two decades, major efforts have focused on improving the survival rate by intensification of combination chemotherapy regimens and employing stem cell transplantation for chemotherapy-resistant patients. More recently, several new and 'renewed' agents have offered the opportunity for a change in the paradigm for the management of both chemo-sensitive and chemo-resistant forms of ALCL...
March 30, 2018: Cancers
https://www.readbyqxmd.com/read/29597249/the-role-of-activator-protein-1-ap-1-family-members-in-cd30-positive-lymphomas
#13
REVIEW
Ines Garces de Los Fayos Alonso, Huan-Chang Liang, Suzanne D Turner, Sabine Lagger, Olaf Merkel, Lukas Kenner
The Activator Protein-1 (AP-1) transcription factor (TF) family, composed of a variety of members including c-JUN, c-FOS and ATF, is involved in mediating many biological processes such as proliferation, differentiation and cell death. Since their discovery, the role of AP-1 TFs in cancer development has been extensively analysed. Multiple in vitro and in vivo studies have highlighted the complexity of these TFs, mainly due to their cell-type specific homo- or hetero-dimerization resulting in diverse transcriptional response profiles...
March 28, 2018: Cancers
https://www.readbyqxmd.com/read/29589643/a-rare-and-isolated-presentation-of-primary-cutaneous-anaplastic-large-cell-lymphoma
#14
Maitri Shah, Manoj Pawar, Vijay Zawar
Primary cutaneous anaplastic large cell lymphoma is a CD30+ lymphoproliferative disorder of the skin characterized by the absence of nodal and visceral involvement, low recurrence rate, spontaneous remission, and tendency to occur in patients older than 20 years. The case presented here is of a 15-year-old boy with grouped papular lesions arranged in an annular fashion with a central clearing on his right arm for 4 months that was diagnosed with a case of anaplastic lymphoma kinase-negative primary cutaneous CD30+ anaplastic large cell lymphoma...
March 2018: Acta Dermatovenerologica Alpina, Panonica, et Adriatica
https://www.readbyqxmd.com/read/29575591/improved-clonality-detection-in-hodgkin-lymphoma-using-a-semi-nested-modification-of-the-biomed-2-pcr-assay-for-igh-and-igk-rearrangements-a-paraffin-embedded-tissue-study
#15
Shusen Han, Ayako Masaki, Yuma Sakamoto, Hisashi Takino, Takayuki Murase, Shinsuke Iida, Hiroshi Inagaki
The BIOMED-2 PCR protocols targeting IGH and IGK genes may be useful for detecting clonality in Hodgkin lymphoma (HL). The clonality detection rates, however, have not been very high with these methods using paraffin-embedded tumor sections. We previously described the usefulness of the semi-nested BIOMED-2 IGH assay in B-cell malignancies. In this study, we devised a novel semi-nested BIOMED-2 IGK assay. Employing 58 cases of classical HL, we carried out the standard BIOMED-2, BIOMED-2 followed by BIOMED-2 re-amplification, and BIOMED-2 followed by semi-nested BIOMED-2, all targeting IGH and IGK, using paraffin-embedded tissues...
March 25, 2018: Pathology International
https://www.readbyqxmd.com/read/29572070/escmid-study-group-for-infections-in-compromised-hosts-esgich-consensus-document-on-the-safety-of-targeted-and-biological-therapies-an-infectious-diseases-perspective-agents-targeting-lymphoid-or-myeloid-cells-surface-antigens-ii-cd22-cd30-cd33-cd38-cd40-slamf
#16
REVIEW
Lubos Drgona, Carlota Gudiol, Simone Lanini, Bernd Salzberger, Giuseppe Ippolito, Małgorzata Mikulska
BACKGROUND: The present review is part of the ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies. AIMS: To review, from an Infectious Diseases perspective, the safety profile of agents targeting CD22, CD30, CD33, CD38, CD40, SLAMF-7 and CCR4 and to suggest preventive recommendations. SOURCES: Computer-based MEDLINE searches with MeSH terms pertaining to each agent or therapeutic family...
March 20, 2018: Clinical Microbiology and Infection
https://www.readbyqxmd.com/read/29568203/role-of-relevant-immune-modulators-and-cytokines-in-hepatocellular-carcinoma-and-premalignant-hepatic-lesions
#17
Abdel-Rahman N Zekri, Somaya El Deeb, Abeer A Bahnassy, Abeer M Badr, Mona S Abdellateif, Gamal Esmat, Hosny Salama, Marwa Mohanad, Ahmed Esam El-Dien, Shimaa Rabah, Assmaa Abd Elkader
AIM: To assess the levels of different immune modulators in patients with hepatocellular carcinoma (HCC), in relation to other hepatic diseases. METHODS: Eighty-eight patients were included in the current study and represented patients with HCC (20), liver cirrhosis (28) and chronic hepatitis (CH; 25), and normal controls (NC; 15). Peripheral blood was isolated for immunophenotyping of active myeloid dendritic cells (mDCs; CD1c and CD40), mature inactive myeloid cells (CD1c and HLA), active plasmacytoid cells (pDCs; CD303 and CD40), mature inactive pDCs (CD30 and HLA), active natural killer (NK) cells (CD56 and CD161), active NK cells (CD56 and CD314) and inactive NK cells (CD56 and CD158) was done by flow cytometry...
March 21, 2018: World Journal of Gastroenterology: WJG
https://www.readbyqxmd.com/read/29567760/blatt-k-cerny-reiterer-s-schwaab-j-et-al-identification-of-the-ki-1-antigen-cd30-as-a-novel-therapeutic-target-in-systemic-mastocytosis-blood-2015-126-26-2832-2841
#18
https://www.readbyqxmd.com/read/29560124/cd30-targeted-oncolytic-viruses-as-novel-therapeutic-approach-against-classical-hodgkin-lymphoma
#19
Julia D S Hanauer, Benjamin Rengstl, Dina Kleinlützum, Johanna Reul, Anett Pfeiffer, Thorsten Friedel, Irene C Schneider, Sebastian Newrzela, Martin-Leo Hansmann, Christian J Buchholz, Alexander Muik
Classical Hodgkin lymphoma (cHL) is a hematopoietic malignancy with a characteristic cellular composition. The tumor mass is made up of infiltrated lymphocytes and other cells of hematologic origin but only very few neoplastic cells that are mainly identified by the diagnostic marker CD30. While most patients with early stage cHL can be cured by standard therapy, treatment options for relapsed or refractory cHL are still not sufficient, although immunotherapy-based approaches for the treatment of cHL patients have gained ground in the last decade...
February 27, 2018: Oncotarget
https://www.readbyqxmd.com/read/29552368/primary-diffuse-large-b-cell-lymphoma-mimicking-hyperplastic-reactive-lesion-lymphoma-of-the-oral-cavity
#20
Liziane Cattelan Donaduzzi, Angélica Reinheimer, Maria Augusta Ramires da Silva, Lucia de Noronha, Aline Cristina Batista Rodrigues Johann, Ademir Franco, Soraya de Azambuja Berti Couto, Paulo Henrique Couto Souza
Objective: To report a case of a challenging oral diagnosis involving a primary diffuse large B cell lymphoma of the oral cavity mimicking a hyperplastic reactive lesion. Case Report: A 72-year-old male patient was referred to the Department of Stomatology presenting a proliferative nodular lesion in the anterior region of the mandible involving the anterior teeth. The clinical examination revealed anterior teeth affected by periodontal disease, suggesting the nodular cession hyperplastic reaction...
2018: Case Reports in Pathology
keyword
keyword
73698
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"